{"protocolSection":{"identificationModule":{"nctId":"NCT05193071","orgStudyIdInfo":{"id":"y (2021) 109"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST)","officialTitle":"Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST): a Prospective, Random, Double Blinded and Multi-center Study"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-07-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-07-28","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-07-28","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-12-31","studyFirstSubmitQcDate":"2021-12-31","studyFirstPostDateStruct":{"date":"2022-01-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-20","lastUpdatePostDateStruct":{"date":"2023-08-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Head of Neurology","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"General Hospital of Shenyang Military Region","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The current guideline recommends to give antithrombotic treatment 24 hours after intravenous thrombolysis in acute ischemic stroke. However, early neurological deterioration will occur in some patients due to no antithrombotic treatment, which is closely associated with poor outcome. The current trial aims to investigate the effectiveness and safety of early antithrombotic treatment after intravenous thrombolysis in minor stroke."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["thrombolysis","minor stroke","early antiplatelet"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1022,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"double antiplatelet group","type":"EXPERIMENTAL","description":"aspirin 100mg plus clopidogrel 300mg","interventionNames":["Drug: Aspirin 100mg; Clopidogrel 300mg"]},{"label":"control group","type":"PLACEBO_COMPARATOR","description":"aspirin placebo plus clopidogrel placebo","interventionNames":["Drug: Aspirin 100mg; Clopidogrel 300mg"]}],"interventions":[{"type":"DRUG","name":"Aspirin 100mg; Clopidogrel 300mg","description":"Aspirin 100mg plus Clopidogrel 300mg will be orally administrated after randomization","armGroupLabels":["control group","double antiplatelet group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The proportion of excellent prognosis","description":"excellent prognosis is defined as modified Rankin Score (mRS) 0-1. The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome","timeFrame":"Day 90"}],"secondaryOutcomes":[{"measure":"The proportion of favorable prognosis","description":"Favorable prognosis is defined as modified Rankin Score (mRS) 0-2. The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome.","timeFrame":"Day 90"},{"measure":"Distribution of modified Rankin Score (mRS)","description":"The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome.","timeFrame":"Day 90"},{"measure":"Changes in National Institute of Health stroke scale (NIHSS)","description":"the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome.","timeFrame":"24 hours, 48 hours, and 10 days"},{"measure":"Occurrence of early neurologyical deterioration (END)","description":"END is defined as more than 2 point increase, but not result of cerebral hemorrhage, compared with baseline at 24 hours","timeFrame":"24 hours"},{"measure":"The incidence of symptomatic intracerebral hemorrhage","description":"any evidence of bleeding on the head CT scan associated with clinically significant neurological deterioration (NIHSS score ≥4 points increase)","timeFrame":"36 hours"},{"measure":"The incidence of any intracerebral hemorrhage","description":"the evidence of bleeding on the head CT or MRI scan","timeFrame":"36 hours"},{"measure":"The incidence of stroke recurrence and other vascular events","timeFrame":"Day 90"},{"measure":"The death due to any cause","timeFrame":"Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Acute ischemic stroke patients who received intravenous thrombolysis within 4.5 hours of onset;\n* NIHSS ≤ 5 within 6 hours after the end of intravenous thrombolysis, and no bleeding transformation was found in head CT examination;\n* Premorbid mRS ≤ 1;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Premorbid mRS≥2;\n* Uncontrolled severe hypertension (systolic pressure \\>180 mmHg or diastolic pressure \\>110 mmHg after drug treatment);\n* Antithrombotic treatment within 24 hours before randomization;\n* Significant dysphagia and inability to take the experimental drug orally;\n* Allergy or contraindication to study drugs;\n* Comorbidity with any serious diseases and life expectancy is less than half a year;\n* Participating in other clinical trials within three months;\n* Patients not suitable for this clinical study considered by researcher","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Hui-sheng Chen","status":"RECRUITING","city":"ShenYang","state":"None Selected","zip":"110840","country":"China","contacts":[{"name":"Hui-sheng Chen","role":"CONTACT","phone":"+862428897511","email":"chszh@aliyun.com"}],"geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Department of Neurology, General Hospital of Northern Theater Command","status":"RECRUITING","city":"Shenyang","zip":"110016","country":"China","contacts":[{"name":"Hui-Sheng Chen, Ph.D.","role":"CONTACT","phone":"+86 13352452086","email":"chszh@aliyun.com"}],"geoPoint":{"lat":41.79222,"lon":123.43278}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Autistic","relevance":"HIGH"},{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}